The effect of Tinzaparin, a low-molecular-weight heparin, on the treatment of blood clots in cancer patients
The largest completed study to date on treatments to reduce recurrence of blood clots in cancer patients, has now been published in JAMA.
The study has shown that Tinzaparin ( Innohep ) has lowered the risk of recurrent venous thromboembolism ( VTE ) compared with Warfarin with a significant reduction in symptomatic deep vein thrombosis and clinically relevant non-major bleeding in cancer patients with symptomatic venous thromboembolism.
Blood clots are one of the leading causes of death in patients with cancer. Approximately 1 in 10 patients with cancer dies from a blood clot related event.
Cancer patients with venous thromboembolism have a substantial risk of blood clots, and optimal treatment to avoid recurrence is vital.
Despite clinical practice guidelines recommending the use of low-molecular-weight heparins ( LMWH), Warfarin remains a frequently used anticoagulant treatment worldwide for cancer patients with recurrent venous thromboembolism.
The CATCH study is a phase III, multinational, concealed, randomised, active-controlled, open-label trial with blinded adjudication.
900 cancer patients from Europe, Africa, Asia, North America and South America were enrolled in the study.
449 patients were treated with Tinzaparin and 451 were treated with Warfarin over a period of 180 days.
During the treatment period, 7.2% of the patients treated with Tinzaparin experienced recurrent blood clots compared to 10.5% of the patients treated with Warfarin.
CATCH is the largest randomized study conducted to date on extended treatment with LMWH to prevent recurrence of VTE in patients with active cancer.
CATCH is a phase III, multinational, concealed, randomised, active-controlled, open-label trial with blinded adjudication assessing the efficacy and safety of long-term ( 6 months ) Tinzaparin therapy ( 175 UI/kg ) versus anticoagulation with Warfarin for the treatment of venous thromboembolism in 900 cancer patients.
For the general population, the standard treatment for acute venous thromboembolism consists of initial therapy with a low-molecular-weight heparin ( LMWH ) followed by longer-term treatment ( 36 months ) with an oral vitamin K antagonist ( VKA ).
Although this approach can be effective for many patients, cancer patients have a substantial risk of recurrent venous thromboembolism.
Several studies have reported incidences of recurrent venous thromboembolism as high as 20% in patients with cancer.
However, studies on how to treat and identify those at risk of recurrent venous thromboembolism are limited.
Moreover, the frequent monitoring and dose adjustments required for vitamin K antagonist treatment have a negative impact on quality of life. ( Xagena2015 )
Source: Leo Pharma, 2015